topotecan has been researched along with cx 5461 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Brajanovski, N; Chan, KT; Cullinane, C; Ellis, S; Hannan, KM; Hannan, RD; Kang, J; Madhamshettiwar, PB; Pearson, RB; Sanij, E; Sheppard, KE; Simpson, KJ; Tancock, MRC; Xuan, J; Yan, S | 1 |
1 other study(ies) available for topotecan and cx 5461
Article | Year |
---|---|
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; DNA Damage; DNA Replication; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Female; G1 Phase Cell Cycle Checkpoints; Genes, BRCA2; Homologous Recombination; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred NOD; Mice, SCID; Naphthyridines; Neoplasm Grading; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; RNA Interference; RNA Polymerase I; Topoisomerase I Inhibitors; Topotecan | 2021 |